Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 18.11
AKCA's Cash-to-Debt is ranked lower than
55% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. AKCA: 18.11 )
Ranked among companies with meaningful Cash-to-Debt only.
AKCA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: 18.11 Max: No Debt
Current: 18.11
0.32
No Debt
Equity-to-Asset 0.67
AKCA's Equity-to-Asset is ranked lower than
52% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AKCA: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
AKCA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.67  Med: 0.67 Max: 0.67
Current: 0.67
Debt-to-Equity 0.08
AKCA's Debt-to-Equity is ranked higher than
75% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. AKCA: 0.08 )
Ranked among companies with meaningful Debt-to-Equity only.
AKCA' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.37  Med: -0.65 Max: 0.08
Current: 0.08
-1.37
0.08
Debt-to-EBITDA -0.14
AKCA's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. AKCA: -0.14 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AKCA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.29  Med: -0.21 Max: -0.14
Current: -0.14
-0.29
-0.14
Piotroski F-Score: 5
Altman Z-Score: 13.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -196.82
AKCA's Operating Margin % is ranked lower than
59% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. AKCA: -196.82 )
Ranked among companies with meaningful Operating Margin % only.
AKCA' s Operating Margin % Range Over the Past 10 Years
Min: -196.82  Med: -196.82 Max: -196.82
Current: -196.82
Net Margin % -198.79
AKCA's Net Margin % is ranked lower than
59% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. AKCA: -198.79 )
Ranked among companies with meaningful Net Margin % only.
AKCA' s Net Margin % Range Over the Past 10 Years
Min: -198.79  Med: -198.79 Max: -198.79
Current: -198.79
ROE % -364.91
AKCA's ROE % is ranked lower than
96% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. AKCA: -364.91 )
Ranked among companies with meaningful ROE % only.
AKCA' s ROE % Range Over the Past 10 Years
Min: -443.59  Med: -222.27 Max: -135.59
Current: -364.91
-443.59
-135.59
ROA % -66.44
AKCA's ROA % is ranked lower than
72% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. AKCA: -66.44 )
Ranked among companies with meaningful ROA % only.
AKCA' s ROA % Range Over the Past 10 Years
Min: -216.85  Med: -185.94 Max: -66.44
Current: -66.44
-216.85
-66.44
ROC (Joel Greenblatt) % -87069.33
AKCA's ROC (Joel Greenblatt) % is ranked lower than
96% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. AKCA: -87069.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AKCA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1228760  Med: -89317.65 Max: -84051.18
Current: -87069.33
-1228760
-84051.18
GuruFocus has detected 2 Warning Signs with Akcea Therapeutics Inc AKCA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AKCA's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NAS:AKCA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:XKRX:006280, SZSE:300294, NYSE:XON, ROCO:4147, NAS:DNLI, LSE:GNS, XMCE:ALM, NAS:PTLA, NAS:GBT, TSE:4974, NAS:CORT, NAS:ONCE, SZSE:002287, SZSE:002653, NAS:SGMO, NAS:ESPR, NAS:RXDX, NAS:MYOK, NAS:IMMU, NAS:XLRN » details
Traded in other countries:1KA.Germany,
Headquarter Location:USA
Akcea Therapeutics Inc is a late stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.

Akcea Therapeutics Inc is a late stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. Its most advanced drug, volanesorsen, has completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.

Ratios

vs
industry
vs
history
PB Ratio 10.26
AKCA's PB Ratio is ranked lower than
66% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. AKCA: 10.26 )
Ranked among companies with meaningful PB Ratio only.
AKCA' s PB Ratio Range Over the Past 10 Years
Min: 5.73  Med: 7.2 Max: 11.85
Current: 10.26
5.73
11.85
PS Ratio 24.47
AKCA's PS Ratio is ranked lower than
58% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AKCA: 24.47 )
Ranked among companies with meaningful PS Ratio only.
AKCA' s PS Ratio Range Over the Past 10 Years
Min: 15  Med: 20.25 Max: 32.87
Current: 24.47
15
32.87
EV-to-EBIT -19.87
AKCA's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. AKCA: -19.87 )
Ranked among companies with meaningful EV-to-EBIT only.
AKCA' s EV-to-EBIT Range Over the Past 10 Years
Min: -20.38  Med: -9.55 Max: -5.4
Current: -19.87
-20.38
-5.4
EV-to-EBITDA -19.91
AKCA's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. AKCA: -19.91 )
Ranked among companies with meaningful EV-to-EBITDA only.
AKCA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.42  Med: -9.6 Max: -5.5
Current: -19.91
-20.42
-5.5
EV-to-Revenue 38.40
AKCA's EV-to-Revenue is ranked lower than
57% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. AKCA: 38.40 )
Ranked among companies with meaningful EV-to-Revenue only.
AKCA' s EV-to-Revenue Range Over the Past 10 Years
Min: 16  Med: 20.3 Max: 34.1
Current: 38.4
16
34.1
Current Ratio 3.30
AKCA's Current Ratio is ranked lower than
58% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. AKCA: 3.30 )
Ranked among companies with meaningful Current Ratio only.
AKCA' s Current Ratio Range Over the Past 10 Years
Min: 0.32  Med: 3.3 Max: 5.99
Current: 3.3
0.32
5.99
Quick Ratio 3.30
AKCA's Quick Ratio is ranked lower than
54% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. AKCA: 3.30 )
Ranked among companies with meaningful Quick Ratio only.
AKCA' s Quick Ratio Range Over the Past 10 Years
Min: 0.32  Med: 3.3 Max: 5.99
Current: 3.3
0.32
5.99
Days Sales Outstanding 35.79
AKCA's Days Sales Outstanding is ranked higher than
73% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. AKCA: 35.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
AKCA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.79  Med: 35.79 Max: 35.79
Current: 35.79

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.78
AKCA's Price-to-Net-Cash is ranked higher than
56% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. AKCA: 10.78 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AKCA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.75  Med: 6.75 Max: 11.03
Current: 10.78
6.75
11.03
Price-to-Net-Current-Asset-Value 10.38
AKCA's Price-to-Net-Current-Asset-Value is ranked higher than
53% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. AKCA: 10.38 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AKCA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.5  Med: 6.5 Max: 10.62
Current: 10.38
6.5
10.62
Price-to-Tangible-Book 10.34
AKCA's Price-to-Tangible-Book is ranked lower than
58% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. AKCA: 10.34 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AKCA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.48  Med: 6.48 Max: 10.58
Current: 10.34
6.48
10.58
Price-to-Median-PS-Value 1.21
AKCA's Price-to-Median-PS-Value is ranked higher than
60% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. AKCA: 1.21 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AKCA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.76  Med: 0.76 Max: 1.24
Current: 1.21
0.76
1.24
Earnings Yield (Greenblatt) % -5.03
AKCA's Earnings Yield (Greenblatt) % is ranked lower than
58% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. AKCA: -5.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AKCA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -18.4  Med: -10.45 Max: -4.9
Current: -5.03
-18.4
-4.9

More Statistics

Revenue (TTM) (Mil) $55.21
EPS (TTM) $ -2.70
52-Week Range $8.10 - 33.99
Shares Outstanding (Mil)85.39

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}